RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Adial Pharmaceuticals Stock

Adial Pharmaceuticals Revenue 2024

Adial Pharmaceuticals Revenue

0 USD

Ticker

ADIL

ISIN

US00688A1060

WKN

A2N38J

In 2024, Adial Pharmaceuticals's sales reached 0 USD, a 0% difference from the 0 USD sales recorded in the previous year.

The Adial Pharmaceuticals Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e45.43-
2028e22.22-
2027e--
2026e--
2025e--
2024e--
2023--
2022--
2021--
2020--
2019--
2018--
2017--
2016--
2015--

Adial Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Adial Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Adial Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Adial Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Adial Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Adial Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Adial Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Adial Pharmaceuticals’s growth potential.

Adial Pharmaceuticals Revenue, EBIT and net profit per share

DateAdial Pharmaceuticals RevenueAdial Pharmaceuticals EBITAdial Pharmaceuticals Net Income
2029e45.43 M undefined0 undefined739,088.3 undefined
2028e22.22 M undefined-4.29 M undefined-146,596.03 undefined
2027e0 undefined-23.65 M undefined-1.05 M undefined
2026e0 undefined-16.9 M undefined-1.1 M undefined
2025e0 undefined-11.53 M undefined-1.63 M undefined
2024e0 undefined-8.48 M undefined-3.71 M undefined
20230 undefined-6.89 M undefined-5.12 M undefined
20220 undefined-13.32 M undefined-12.73 M undefined
20210 undefined-17.74 M undefined-19.42 M undefined
20200 undefined-10.93 M undefined-10.89 M undefined
20190 undefined-8.24 M undefined-8.59 M undefined
20180 undefined-6.99 M undefined-11.63 M undefined
20170 undefined-1 M undefined-1.14 M undefined
20160 undefined-410,000 undefined-420,000 undefined
20150 undefined-800,000 undefined-820,000 undefined

Adial Pharmaceuticals stock margins

The Adial Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Adial Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Adial Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Adial Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Adial Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Adial Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Adial Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Adial Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Adial Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Adial Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Adial Pharmaceuticals Margin History

Adial Pharmaceuticals Gross marginAdial Pharmaceuticals Profit marginAdial Pharmaceuticals EBIT marginAdial Pharmaceuticals Profit margin
2029e0 %0 %1.63 %
2028e0 %-19.31 %-0.66 %
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %

Adial Pharmaceuticals Aktienanalyse

What does Adial Pharmaceuticals do?

Adial Pharmaceuticals Inc was founded in 2010 in Charlottesville, Virginia. The company focuses on the discovery and development of drugs for the treatment of addiction disorders such as alcohol and nicotine dependence. Adial's business model is based on the belief that current therapies for addiction disorders are insufficient and that there is a need for more targeted and effective medications. The company develops drugs that target specific biological processes in the brain associated with addiction disorders. Adial has several divisions, including research and development, manufacturing, and clinical studies. The company has a promising pipeline of candidate molecules in various stages of development. The flagship product of Adial is AD04, which was developed for the treatment of alcohol dependence. AD04 is based on a novel approach called genetic prediction. It targets a specific biological process known as the opioid receptor and blocks it to reduce the craving for alcohol. Adial has recently completed a Phase 3 clinical trial with AD04, which has yielded promising results. The results suggest that AD04 is effective in reducing alcohol consumption in people with the genetic prediction. Adial plans to market AD04 in the USA and Europe. Adial also has a collaboration with the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) in the USA. This collaboration focuses on the development of drugs for the treatment of nicotine dependence. Adial has developed a promising molecule candidate that is currently being tested in Phase 2 clinical trials. Adial also has a division for manufacturing and technology partnerships. The company collaborates with various stakeholders in the pharmaceutical and biotech industry to develop technological solutions that can accelerate the development of new drugs. Overall, Adial Pharmaceuticals has focused on the discovery and development of drugs for the treatment of addiction disorders. The company has a promising pipeline of candidate molecules and has completed clinical trials with its flagship product AD04. Adial is also working in collaboration with renowned institutions such as NIDA of the NIH to expand the scope of its research and development. Adial Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Adial Pharmaceuticals's Sales Figures

The sales figures of Adial Pharmaceuticals originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Adial Pharmaceuticals’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Adial Pharmaceuticals's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Adial Pharmaceuticals’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Adial Pharmaceuticals stock

How much revenue did Adial Pharmaceuticals generate this year?

Adial Pharmaceuticals has achieved a revenue of 0 USD this year.

How much was the turnover of the company Adial Pharmaceuticals compared to the previous year?

The revenue of Adial Pharmaceuticals has increased by 0% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Adial Pharmaceuticals?

The revenue of Adial Pharmaceuticals is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Adial Pharmaceuticals measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Adial Pharmaceuticals so important for investors?

The revenue of Adial Pharmaceuticals is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Adial Pharmaceuticals pay?

Over the past 12 months, Adial Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Adial Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Adial Pharmaceuticals?

The current dividend yield of Adial Pharmaceuticals is .

When does Adial Pharmaceuticals pay dividends?

Adial Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Adial Pharmaceuticals?

Adial Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Adial Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Adial Pharmaceuticals located?

Adial Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Adial Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Adial Pharmaceuticals from 11/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/19/2024.

When did Adial Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/19/2024.

What was the dividend of Adial Pharmaceuticals in the year 2023?

In the year 2023, Adial Pharmaceuticals distributed 0 USD as dividends.

In which currency does Adial Pharmaceuticals pay out the dividend?

The dividends of Adial Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Adial Pharmaceuticals

Our stock analysis for Adial Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adial Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.